Biopharma industry endorses Pazdur for FDA commissioner role
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week,…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Podcast: UK targets speedy clinical trial set-ups with 150-day benchmark
Faced with growing competition in the global clinical trials landscape, many countries are reforming regulatory frameworks in a bid to…
-
Countries compete to reform trials in a bid to attract global sponsors
Clinical trial reforms have become abundant across the global pharmaceutical industry as regions look to stake their claim in attracting…
-
Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
-
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to…
-
JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.…
-
JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership
Eli Lilly and NVIDIA will establish a new artificial intelligence (AI) co-innovation lab, as the companies look to use each…
-
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…